ERBB2 and breast cancer: Numerous randomized controlled trials (RCTs) investigating TKIs such as lapatinib, afatinib, neratinib, pyrotinib, and tucatinib are conducted in HER2-positive BC patients [14], and suggest favorable efficacy and safety.